首页> 美国卫生研究院文献>International Journal of Molecular Sciences >An Ameliorated Prediction of Drug–Target Interactions Based on Multi-Scale Discrete Wavelet Transform and Network Features
【2h】

An Ameliorated Prediction of Drug–Target Interactions Based on Multi-Scale Discrete Wavelet Transform and Network Features

机译:基于多尺度离散小波变换和网络特征的药物-药物相互作用的改进预测

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The prediction of drug–target interactions (DTIs) via computational technology plays a crucial role in reducing the experimental cost. A variety of state-of-the-art methods have been proposed to improve the accuracy of DTI predictions. In this paper, we propose a kind of drug–target interactions predictor adopting multi-scale discrete wavelet transform and network features (named as DAWN) in order to solve the DTIs prediction problem. We encode the drug molecule by a substructure fingerprint with a dictionary of substructure patterns. Simultaneously, we apply the discrete wavelet transform (DWT) to extract features from target sequences. Then, we concatenate and normalize the target, drug, and network features to construct feature vectors. The prediction model is obtained by feeding these feature vectors into the support vector machine (SVM) classifier. Extensive experimental results show that the prediction ability of DAWN has a compatibility among other DTI prediction schemes. The prediction areas under the precision–recall curves (AUPRs) of four datasets are 0.895 (Enzyme), 0.921 (Ion Channel), 0.786 (guanosine-binding protein coupled receptor, GPCR), and 0.603 (Nuclear Receptor), respectively.
机译:通过计算技术预测药物-靶标相互作用(DTI)在降低实验成本中起着至关重要的作用。已经提出了各种最新技术来提高DTI预测的准确性。在本文中,我们提出了一种采用多尺度离散小波变换和网络特征(称为DAWN)的药物-目标相互作用预测器,以解决DTI的预测问题。我们通过具有亚结构模式字典的亚结构指纹来编码药物分子。同时,我们应用离散小波变换(DWT)从目标序列中提取特征。然后,我们将目标,药物和网络特征连接并归一化以构建特征向量。通过将这些特征向量输入到支持向量机(SVM)分类器中来获得预测模型。大量的实验结果表明,DAWN的预测能力与其他DTI预测方案具有兼容性。四个数据集的精确召回曲线(AUPR)下的预测区域分别为0.895(酶),0.921(离子通道),0.786(鸟苷结合蛋白偶联受体,GPCR)和0.603(核受体)。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号